JR I concur solidly with much of what you just posted, and it definitely looks like I missed a decimal.lol
Since the stock does not trade, and there is no significant positive actions yet since June, or I should say transparent ones which I can readily see, this is merely a Venting board and that will change for the 98% of us if Peter actually does execute somethings which generate shareholder value.
For now judging on what others posted and I tried to summarize, Peter best have a very very close look at his pricing, on the few things checked, it appeared RXPCinc is 2x the going rate of some doing similar functions on the net. When a common drug like Lipitor and its generic counterpart are that far off price wise, you have to wonder what the heck is going on.
From what was given the board on Liptor/Generic pricing he seems better served now from the looks just to buy the drug from his competition and mark it up 20% and try to sell it on his site with the competition drop shipping.
I don't see how they advertise pricing 1/2 of Peter's for that drug and he thinks he has a viable concept?
News 
Market Data 
Discover 
AI
